MagQu to Exhibit at AAIC 2026 in London
MagQu will be exhibiting at the Alzheimer’s Association International Conference® 2026, taking place July 12 to 15, 2026, in London, United Kingdom, and online. Visit MagQu at Booth 1308 to learn more about ImmunoMagnetic Reduction technology for plasma biomarker measurement in Alzheimer’s disease and neurodegenerative disease research. The official AAIC website describes the conference as a global forum for advancing dementia science and lists the 2026 meeting in London and online.
AAIC brings together researchers, clinicians, dementia professionals, industry partners, and laboratory leaders to discuss scientific progress in Alzheimer’s disease and related dementias. For MagQu, AAIC 2026 will be an important opportunity to connect with research groups, clinical laboratories, and collaborators interested in blood-based biomarker testing for neurodegenerative diseases.
At AAIC 2026, MagQu will highlight its ImmunoMagnetic Reduction, or IMR, technology, a highly sensitive assay platform developed for measuring biomarkers in plasma. MagQu’s biomarker portfolio includes targets associated with Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions, including Aβ1-40, Aβ1-42, Total Tau, p-Tau181, α-synuclein, TDP-43, NfL, GFAP, BDNF, UCH-L1, and p-Tau217 for research use.
Blood-based biomarkers are increasingly important in dementia research because they may support earlier assessment, longitudinal monitoring, and broader access compared with more invasive or costly approaches. MagQu’s IMR platform is designed to support ultra-sensitive plasma biomarker measurement, with low detection limits reported at the fg/mL level for multiple neurodegenerative disease biomarkers.
Visitors to Booth 1308 can discuss:
Plasma biomarker assay services for research studies
IMR technology and assay workflow
Alzheimer’s disease and Parkinson’s disease biomarker panels
Clinical and laboratory collaboration opportunities
Potential partnerships for research-use and future clinical applications
MagQu welcomes conversations with academic researchers, neurologists, clinical laboratories, pharmaceutical teams, and organizations developing programs in Alzheimer’s disease, Parkinson’s disease, and broader neurodegenerative disease research.
To arrange a meeting during AAIC 2026, please contact info@magqu.us.